Across these AAIC presentations, we are showing how AC Immune’s Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase 1 with a profile supporting an orally delivered CNS therapy; and our alpha-synuclein Morphomer® program demonstrates potent, brain-penetrant inhibition of pathology with in vivo neuroprotective effects. Together, these data reinforce the opportunity to build biomarker-led therapeutic programs for major neurodegenerative diseases.

Oral Presentation

Discovery and initial clinical evaluation of [18F]ACI-19626, a first-in-class TDP-43 PET tracer

Presenter: Dr. Tamara Seredinina

Session: Developing Topics in ADRD Diagnostics

Date/Time: July 15, 8:00 – 8:45 AM BST (GMT+1)

Location: Hall S11

Poster Presentations

Novel potent brain penetrant NLRP3 inhibitor ACI-19764 demonstrates efficacy in models of neuroinflammation

Presenter: Dr. Chantal Bazenet

Session: Drug Development, Human

Date/Time: July 12, 7:30 AM – 4:15 PM BST (GMT+1)

Location: Exhibit Hall (# Sunday-0177)

Development of an aggregation inhibitor targeting alpha-synuclein pathology

Presenter: Dr. Francesca Capotosti

Session: Drug Development, Nonhuman

Date/Time: July 14, 7:30 AM – 4:15 PM BST (GMT+1)

Location: Exhibit Hall (# Tuesday-0074)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.